| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.1 | 0.04 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.063 | 0.04 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | 0.065 | 0.04 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | -0.15 | 0.04 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | 0.097 | 0.05 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | 0.071 | 0.05 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.066 | 0.05 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | 0.073 | 0.05 |
| mRNA | ATRA | FIMM | pan-cancer | AAC | -0.3 | 0.05 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | 0.074 | 0.05 |